PMID- 30549362
OWN - NLM
STAT- MEDLINE
DCOM- 20200909
LR  - 20210109
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Print)
IS  - 1043-3074 (Linking)
VI  - 41
IP  - 2
DP  - 2019 Feb
TI  - HLA class II expression on tumor cells and low numbers of tumor-associated 
      macrophages predict clinical outcome in oropharyngeal cancer.
PG  - 463-478
LID - 10.1002/hed.25442 [doi]
AB  - BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal squamous cell 
      carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor 
      microenvironment might contribute to the improved survival of HPV-positive OPSCC 
      patient. METHODS: A comprehensive multivariate analysis with clinical and immune 
      variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD-L1), 
      programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 
      OPSCC patients. RESULTS: We found an inverse correlation between the expression 
      of HLA class II molecules on tumor cells and CD68+ CD163+ tumor-associated 
      macrophages (TAMs). High HLA-DP/DQ/DR expression and low number of TAMs were 
      associated with longer disease-specific survival and disease-free survival (DFS). 
      Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter 
      DFS in multivariate analysis. CONCLUSIONS: \We identified new prognostic markers 
      for patients with oropharyngeal cancer, which can be used for selecting patients 
      that can benefit from immunotherapy.
CI  - (c) 2018 The Authors. Head & Neck published by Wiley Periodicals, Inc.
FAU - Cioni, Bianca
AU  - Cioni B
AUID- ORCID: 0000-0003-2684-4255
AD  - Division of Oncogenomics, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
FAU - Jordanova, Ekaterina S
AU  - Jordanova ES
AUID- ORCID: 0000-0002-8121-1322
AD  - Center for Gynecologic Oncology, VU University Medical Center, Amsterdam, The 
      Netherlands.
FAU - Hooijberg, Erik
AU  - Hooijberg E
AUID- ORCID: 0000-0002-4482-2191
AD  - Division of Pathology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, 
      Amsterdam, The Netherlands.
FAU - van der Linden, Rianne
AU  - van der Linden R
AD  - Division of Pathology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, 
      Amsterdam, The Netherlands.
FAU - de Menezes, Renee X
AU  - de Menezes RX
AD  - Division of Epidemiology and Biostatistics, VU University Medical Center, 
      Amsterdam, The Netherlands.
FAU - Tan, Katherine
AU  - Tan K
AD  - Division of Medical Oncology, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
FAU - Willems, Stefan
AU  - Willems S
AD  - Division of Pathology, Antoni van Leeuwenhoek, The Netherlands Cancer Institute, 
      Amsterdam, The Netherlands.
FAU - Elbers, Joris B W
AU  - Elbers JBW
AUID- ORCID: 0000-0003-1537-4139
AD  - Division of Head and Neck Surgery, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
AD  - Division of Radiation Oncology, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
FAU - Broeks, Annegien
AU  - Broeks A
AD  - Core Facility Molecular Pathology, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
FAU - Bergman, Andries M
AU  - Bergman AM
AD  - Division of Oncogenomics, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
AD  - Division of Medical Oncology, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
FAU - Zuur, Charlotte L
AU  - Zuur CL
AD  - Division of Head and Neck Surgery, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
FAU - de Boer, Jan Paul
AU  - de Boer JP
AD  - Division of Medical Oncology, Antoni van Leeuwenhoek, The Netherlands Cancer 
      Institute, Amsterdam, The Netherlands.
LA  - eng
GR  - 58593 EEG-CEC TIMCC 317445/Marie Curie - Timcc/International
GR  - Marie Curie ITN-TIMCC/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181214
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (HLA-D Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Aged
MH  - B7-H1 Antigen/metabolism
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Female
MH  - HLA-D Antigens/*metabolism
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Humans
MH  - Macrophages
MH  - Male
MH  - Middle Aged
MH  - Oropharyngeal Neoplasms/*metabolism/mortality/therapy
MH  - Papillomaviridae
MH  - Papillomavirus Infections/metabolism/pathology
MH  - Programmed Cell Death 1 Receptor/metabolism
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Tumor Microenvironment
PMC - PMC6519285
OTO - NOTNLM
OT  - HLA-II
OT  - HPV infection
OT  - TAMs
OT  - microenvironment
OT  - oropharyngeal cancer
COIS- The authors declare no potential conflicts of interest.
EDAT- 2018/12/15 06:00
MHDA- 2020/09/10 06:00
PMCR- 2019/05/15
CRDT- 2018/12/15 06:00
PHST- 2017/11/29 00:00 [received]
PHST- 2018/06/17 00:00 [revised]
PHST- 2018/09/21 00:00 [accepted]
PHST- 2018/12/15 06:00 [pubmed]
PHST- 2020/09/10 06:00 [medline]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2019/05/15 00:00 [pmc-release]
AID - HED25442 [pii]
AID - 10.1002/hed.25442 [doi]
PST - ppublish
SO  - Head Neck. 2019 Feb;41(2):463-478. doi: 10.1002/hed.25442. Epub 2018 Dec 14.